Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations

PLoS ONE

Volumn 2, Issue 11, 2007, Pages

  Choi, Kuicheon ^a   Creighton, Chad J ^b   Stivers, David ^a   Fujimoto, Nobukazu ^a   Kurie, Jonathan M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR; GEFITINIB; TRANSCRIPTOME; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL MUTANT; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE PROBE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; SOMATIC MUTATION; WILD TYPE; COHORT ANALYSIS; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COHORT STUDIES; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION, GENETIC;

EID: 43249083693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001226     Document Type: Article

References (38)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc.Natl.Acad. Sci.U.S.A. 101: 13306-13311.
4. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, et al. (2006) Lung abdenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510.
5. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, et al. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9: 485-495.
6. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, et al. (2006) Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66: 2116-2128.
7. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
8. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, et al. (2005) High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65: 11478-11485.
9. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, et al. (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant-proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163-8171.
10. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, et al. (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS.Med 2: e313.
11. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derivid EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.
12. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, et al. (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell linen. Proc.Natl.Acad.Sci.U.S.A. 102: 3788-3793.
13. Song L, Morris M, Bagui T, Lee FY, Jove R, et al. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66: 5542-5548.
14. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, et al. (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth for receptor-dependent cell lines. Am J Pathol 170: 366-376.
15. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al. (2002) Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat.Med 8: 816-824.
16. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc.Natl.Acad. Sci.U.S.A. 98: 13790-13795.
17. Riely GJ, Politi KA, Miller VA, Pao W (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12: 7232-7241.
18. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, et al. (2006) Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 66: 3903-3911.
19. Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, et al. (2005) Probabilistic model of the human protein-protein interaction network. Nature.Biotechnol 23: 951-959.
20. Jeong H, Mason SP, Barabasi AL, Oltvai ZN (2001) Lethality and centrality in protein networks Nature 411: 41-42.
21. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916.
22. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, et al. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844.
23. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl.Cancer Inst 97: 339-346.
24. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS (2003) Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 162: 1037-1042.
25. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, et al. (2005) A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 8: 111-118.
26. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, et al. (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026.
27. Liu M, Yang SC, Sharma S, Lou J, Cui X, et al. (2007) EGFR Signaling is Required for TGF-{beta}l-mediated COX-2 Induction in Human Bronchial Epithelial Cells. Am J Respir Cell Mol Biol.
28. Wu R, Abramson AL, Shikowitz MJ, Dannenberg AJ, Steinberg BM (2005) Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/ extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clin Cancer Res 11: 6155-6161.
29. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
30. Kobayashi M, Saitoh S, Tanimura N, Takahashi K, Kawasaki K, et al. (2006) Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 176: 6211-6218.
31. Lavergne E, Combadiere B, Bonduelle O, Iga M, Gao JL, et al. (2003) Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 63: 7468-7474.
32. Fujimoto K, Imaizumi T, Yoshida H, Takanashi S, Okumura K, et al (2001) Interferon-gamma stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am J Respir Cell Mol Bio 25: 233-238.
33. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A (2004) CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64: 4693-4698.
34. Creighton C, Kuick R, Misek DE, Rickman DS, Brichory FM, et al. (2003) Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol 4: R46.
35. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 100: 9440-5.
36. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, et al. (2004) The database of interacting proteins:2004 update. Nucleic Acids Res 32: D449-51.
37. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc.Natl Acad.Sci.U.S.A. 95: 14863-14868.
38. Saldanha AJ (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20: 3246-3248.